- Innate Pharma SA KOL Event TranscriptDec 12, 2023
- Q3 2023 Innate Pharma SA Corporate Sales Call TranscriptNov 14, 2023
- Half Year 2023 Innate Pharma SA Earnings Call TranscriptSep 14, 2023$3.07 (+0.22%)Earnings
- Q1 2023 Innate Pharma SA Earnings Call TranscriptMay 10, 2023$2.94 (-3.77%)Earnings
- Q4 2022 Innate Pharma SA Earnings Call TranscriptMar 23, 2023$2.67 (-11.88%)Earnings
- Q3 2022 Innate Pharma SA Earnings Call TranscriptNov 14, 2022$2.48 (+8.30%)Earnings
- Q2 2022 Innate Pharma SA Earnings Call TranscriptSep 15, 2022$2.54 (+3.25%)Earnings
- Q1 2022 Innate Pharma SA Earnings Call TranscriptMay 10, 2022$2.72 (+0.56%)Earnings
- Q4 2021 Innate Pharma SA Earnings Call TranscriptMar 24, 2022$3.36 (-3.17%)Earnings
- Q3 2021 Innate Pharma SA Corporate Sales Call TranscriptNov 16, 2021
- Q2 2021 Innate Pharma SA Earnings Call TranscriptSep 15, 2021$5.58 (+2.01%)Earnings
- Innate Pharma SA To Discuss Virtual Investor Event-Call TranscriptJun 23, 2021
- Q1 2021 Innate Pharma SA Earnings Call TranscriptMay 11, 2021$4.1 (+6.22%)Earnings
- Q4 2020 Innate Pharma SA Earnings Call TranscriptMar 18, 2021$4.45 (-3.17%)Earnings
Q1 2023 Innate Pharma SA Earnings Call Transcript
Thank you for joining the Innate Pharma Publication of Revenue for First Quarter 2023 Conference Call. (Operator Instructions) Finally, I would like to remind all participants that this call is being recorded.
Without further ado, I am pleased to introduce Henry Wheeler, Vice President, Investor Relations and Communications. Henry, over to you.
Thank you. Good morning, good afternoon, and welcome, everyone. This morning, Innate issued a press release providing a business update for Q1 2023. We look forward to highlighting the progress made during the year to-date as well as addressing future goals and milestones. The press release and today's presentation are both available on the IR section of our website.
On Slide 2, before we start, I'd like to remind you that we will make forward-looking statements regarding the financial outlook in addition to regulatory and product plan development. These statements are subject to risks and uncertainties that may cause actual results to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)